Schwab Charles Investment Management Inc. boosted its position in Humana Inc (NYSE:HUM) by 25.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 649,364 shares of the insurance provider’s stock after buying an additional 131,124 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Humana were worth $156,250,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in HUM. BlackRock Inc. increased its position in Humana by 2,281.7% in the first quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock worth $2,553,487,000 after buying an additional 11,867,056 shares during the period. FMR LLC increased its position in Humana by 57.9% in the first quarter. FMR LLC now owns 5,050,853 shares of the insurance provider’s stock worth $1,041,184,000 after buying an additional 1,851,197 shares during the period. Renaissance Technologies LLC increased its position in Humana by 84.3% in the first quarter. Renaissance Technologies LLC now owns 2,691,700 shares of the insurance provider’s stock worth $554,867,000 after buying an additional 1,231,400 shares during the period. Wellington Management Group LLP increased its position in Humana by 2,651.1% in the first quarter. Wellington Management Group LLP now owns 775,755 shares of the insurance provider’s stock worth $159,915,000 after buying an additional 747,557 shares during the period. Finally, AQR Capital Management LLC increased its position in Humana by 413.8% in the first quarter. AQR Capital Management LLC now owns 736,019 shares of the insurance provider’s stock worth $151,723,000 after buying an additional 592,772 shares during the period. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Humana Inc (HUM) opened at 249.99 on Friday. The stock has a market cap of $36.13 billion, a price-to-earnings ratio of 20.57 and a beta of 0.91. The stock’s 50 day moving average price is $239.62 and its 200-day moving average price is $222.88. Humana Inc has a 12 month low of $163.50 and a 12 month high of $255.27.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, topping analysts’ consensus estimates of $3.08 by $0.41. The business had revenue of $13.53 billion during the quarter, compared to the consensus estimate of $13.61 billion. Humana had a net margin of 4.80% and a return on equity of 24.61%. During the same quarter in the prior year, the firm posted $2.30 earnings per share. Equities analysts expect that Humana Inc will post $11.55 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/schwab-charles-investment-management-inc-increases-stake-in-humana-inc-hum/1477567.html.

A number of equities analysts recently commented on HUM shares. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $237.00 target price on the stock in a report on Tuesday, April 18th. Citigroup Inc. started coverage on Humana in a report on Wednesday, June 28th. They issued a “buy” rating and a $275.00 target price on the stock. Evercore ISI reaffirmed an “outperform” rating and issued a $240.00 target price on shares of Humana in a report on Tuesday, April 25th. BidaskClub raised Humana from a “hold” rating to a “buy” rating in a report on Wednesday, June 21st. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $230.00 target price (up from $221.00) on shares of Humana in a report on Thursday, May 4th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company’s stock. Humana has an average rating of “Buy” and an average target price of $243.65.

In related news, SVP Brian P. Leclaire sold 4,971 shares of the company’s stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the completion of the transaction, the senior vice president now owns 14,258 shares in the company, valued at approximately $3,421,920. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Heidi S. Margulis sold 1,500 shares of the company’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $231.96, for a total transaction of $347,940.00. Following the transaction, the vice president now owns 8,150 shares of the company’s stock, valued at approximately $1,890,474. The disclosure for this sale can be found here. Corporate insiders own 0.80% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.